Tags

Type your tag names separated by a space and hit enter

A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia.

Abstract

OBJECTIVE

To study the effect of fluoxetine (FL) and amitriptyline (AM), alone and in combination, in patients with fibromyalgia (FM).

METHODS

Nineteen patients with FM completed a randomized, double-blind crossover study, which consisted of 4 6-week trials of FL (20 mg), AM (25 mg), a combination of FL and AM, or placebo. Patients were evaluated on the first and last day of each trial period. Outcome measures included a tender point score, the Fibromyalgia Impact Questionnaire (FIQ), the Beck Depression Inventory (BDI) scale, and visual analog scales (VAS) for global well-being (1 completed by the physician and 1 by the patient), pain, sleep trouble, fatigue, and feeling refreshed upon awakening.

RESULTS

Both FL and AM were associated with significantly improved scores on the FIQ and on the VAS for pain, global well-being, and sleep disturbances. When combined, the 2 treatments worked better than either medication alone. Similar, but nonsignificant, improvement occurred in the BDI scale, the physician global VAS, and the VAS for fatigue and feeling refreshed upon awakening. Trends were less clear for the tender point score.

CONCLUSION

Both FL and AM are effective treatments for FM, and they work better in combination than either medication alone.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Newton-Wellesley Hospital, Massachusette, USA.

    , , ,

    Source

    Arthritis and rheumatism 39:11 1996 Nov pg 1852-9

    MeSH

    Adolescent
    Adult
    Amitriptyline
    Analysis of Variance
    Double-Blind Method
    Drug Therapy, Combination
    Female
    Fibromyalgia
    Fluoxetine
    Humans
    Male
    Middle Aged
    Serotonin Uptake Inhibitors
    Treatment Outcome

    Pub Type(s)

    Clinical Trial
    Journal Article
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    8912507

    Citation

    Goldenberg, D, et al. "A Randomized, Double-blind Crossover Trial of Fluoxetine and Amitriptyline in the Treatment of Fibromyalgia." Arthritis and Rheumatism, vol. 39, no. 11, 1996, pp. 1852-9.
    Goldenberg D, Mayskiy M, Mossey C, et al. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum. 1996;39(11):1852-9.
    Goldenberg, D., Mayskiy, M., Mossey, C., Ruthazer, R., & Schmid, C. (1996). A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism, 39(11), pp. 1852-9.
    Goldenberg D, et al. A Randomized, Double-blind Crossover Trial of Fluoxetine and Amitriptyline in the Treatment of Fibromyalgia. Arthritis Rheum. 1996;39(11):1852-9. PubMed PMID: 8912507.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. AU - Goldenberg,D, AU - Mayskiy,M, AU - Mossey,C, AU - Ruthazer,R, AU - Schmid,C, PY - 1996/11/1/pubmed PY - 1996/11/1/medline PY - 1996/11/1/entrez SP - 1852 EP - 9 JF - Arthritis and rheumatism JO - Arthritis Rheum. VL - 39 IS - 11 N2 - OBJECTIVE: To study the effect of fluoxetine (FL) and amitriptyline (AM), alone and in combination, in patients with fibromyalgia (FM). METHODS: Nineteen patients with FM completed a randomized, double-blind crossover study, which consisted of 4 6-week trials of FL (20 mg), AM (25 mg), a combination of FL and AM, or placebo. Patients were evaluated on the first and last day of each trial period. Outcome measures included a tender point score, the Fibromyalgia Impact Questionnaire (FIQ), the Beck Depression Inventory (BDI) scale, and visual analog scales (VAS) for global well-being (1 completed by the physician and 1 by the patient), pain, sleep trouble, fatigue, and feeling refreshed upon awakening. RESULTS: Both FL and AM were associated with significantly improved scores on the FIQ and on the VAS for pain, global well-being, and sleep disturbances. When combined, the 2 treatments worked better than either medication alone. Similar, but nonsignificant, improvement occurred in the BDI scale, the physician global VAS, and the VAS for fatigue and feeling refreshed upon awakening. Trends were less clear for the tender point score. CONCLUSION: Both FL and AM are effective treatments for FM, and they work better in combination than either medication alone. SN - 0004-3591 UR - https://www.unboundmedicine.com/medline/citation/8912507/full_citation L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0004-3591&date=1996&volume=39&issue=11&spage=1852 DB - PRIME DP - Unbound Medicine ER -